For indikationen skizofreni vurderede CHMP den foreslåede dosering og var af den opfattelse, at selv om 8 mg dosis kunne betragtes som en behandlingsmulighed for visse patienter med skizofreni, bør de behandlende læger individualisere behandlingen og benytte den laveste effektive dosis for hver enkelt patient med en måldosis på 4 til 6 mg/ dag.
For the indication in Schizophrenia, the CHMP assessed the proposed dosing, and was of the opinion that although the 8 mg dose could be considered as a treatment option for particular patients with schizophrenia, treating physicians should individualise treatment and use the lowest efficacious dose for each patient with a target dose of 4 to 6 mg/ day.